Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
11 current organization shown on this profile
Board positions
11 supported by public sources, 0 supplied by the profile owner
Committee roles
Not establishedNo committee role is currently confirmed by the cited sources
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Co-founded GRI Operations in 2009 and served as consultant with CMO title from August 2017 to April 2023. Over 20 years in biotechnology and pharmaceutical industries with CEO experience at Sublimity Therapeutics and CMO roles at Cynapsus. Ph.D. in immunology from McMaster University.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

GRI Bio, Inc.

2025-07-11 · current

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

GRI Bio, Inc.

Open GRI Bio, Inc. profile →

Director at GRI Bio, Inc.

2025-07-11 → End not stated

current · source reported

Observed: 2026-09-27

GRI Bio, Inc.GRI Bio, Inc.Albert Agro, Ph.D.

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingGRI 10-K executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Other Company Role, Technology background.Open sourceSource 2 · Sec ProxyPublic profile sourceSupports Director at GRI Bio, Inc. (NASDAQ: GRI).Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:albert-agro-ph-d
Record version
public-0

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. GRI 10-K executive officers

    sec filing · Source published: Jan 30, 2026 · Retrieved: May 16, 2026

    Supports 6 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at GRI Bio, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Chief Medical Officer · Claim reviewed: May 16, 2026
    • Other Company Role: Albert Agro, Ph.D. is also linked to Jocasta Neuroscience Inc. as Chief Executive Officer. · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  2. Open source

    sec proxy · Source published: Jul 11, 2025 · Retrieved: Sep 2, 2026

    Supports 1 claim
    • Professional Role: Director at GRI Bio, Inc. · Claim reviewed: May 16, 2026

  3. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of GRI Bio, Inc. · Claim reviewed: May 16, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · Source reportedAI and ML experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board membership · Source reportedServes on the board of GRI Bio, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Cybersecurity experience · Source reportedCybersecurity experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at GRI Bio, Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: Chief Medical Officer1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Other Company Role · Source reportedAlbert Agro, Ph.D. is also linked to Jocasta Neuroscience Inc. as Chief Executive Officer.1 source
Verification
Source reported
Confidence
70%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Technology background · Source reportedTechnology background: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

View all sources3 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Other Company Role · Technology background

  2. https://www.sec.gov/Archives/edgar/data/1824293/000182429325000089/a2025proxystatement.htm

    Sec Proxy · Tier not stated · Reviewed Sep 2, 2026

    Supports: Director at GRI Bio, Inc. (NASDAQ: GRI)

  3. https://www.sec.gov/Archives/edgar/data/1824293/000182429325000089/a2025proxystatement.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership